While BPC-157 peptide therapy promotes healing, stopping use wont cause withdrawal but may gradually reduce its effects
Moreover, increased level of GLP-1 was detected in mice with colitis after DPP-IV inhibitor treatment when compared with untreated mice (Yazbeck et al
7 The GLP-1 receptor (GLP-1R) is a G protein-coupled receptor that, when activated, triggers complex intracellular signaling cascades
Concurrently, triple GIP, GLP1 and glucagon receptor agonists such as retatrutide are around the corner, which have impressive effects on glycaemic control, obesity and fatty liver disease [59, 60]
Thus, the participants selected in these two clinical trials may have been those with the most severe metabolic abnormalities and most expected to respond to these treatments